University of Oklahoma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Oklahoma sits in the top decile of US sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count).
University of Oklahoma: 358 sponsored US clinical trials, 80 recruiting.
University of Oklahoma sponsors 358 registered US clinical trials on ClinicalTrials.gov, 80 of them currently recruiting, and 196 completed. 26 of these trials are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 6 trials.
Top-decile sponsor footprint
University of Oklahoma ranks in the top decile of sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 240 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
358 total, page 1 of 8
Dietary Fiber and Time Restricted Eating
NCT07219706
Fiber mHealth Intervention for Prediabetes
NCT07491653
Reset Challenge: Reducing High-risk Drinking for Cancer Prevention
NCT07591428
Empowered Relief® for Cancer Survivors With Chronic Pain
NCT07578376
Acute Pharmacokinetics of Create Wellness Gummies in Healthy Adults
NCT07579455
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
NCT06960798
Efficacy of the Buzzy System on Pain and Fear Reduction in Elbow Fracture Pin Removal
NCT07520851
Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)
NCT07162935
Program in Oncology for Tribal Health Systems.
NCT07217574
The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study
NCT07226310
Promoting Active Living Among People With Metastatic Breast Cancer
NCT07238023
Postural Control in Adults
NCT07554118
Circulating Tumor DNA Response In Urothelial Cancer
NCT07183319
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
NCT07223541
Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
NCT07254910
The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer
NCT07622914
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
NCT07014618
Meloxicam in Mohs Micrographic Surgery
NCT07200544
The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults
NCT07209683
Using Light Therapy for Mild Cognitive Impairment
NCT07651787
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
NCT05617716
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
NCT07080788
Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
NCT06651359
Empowering Cessation ACS South Region
NCT06820034
Connect2Care: Prostate Cancer Education and Screenings for African American Men
NCT07055165
Attitudes and Perceptions Attitudes and Smoking Perceptions in the Real Environment -II
NCT06668350
Evaluating a One-Year Version of the Parent-Child Assistance Program
NCT06163651
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
NCT06488781
Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes
NCT06725953
Efficacy of a Smartphone-Based JITAI to Reduce Drinking Among Adults Experiencing Homelessness
NCT06821295
Cooperative Extension and Cancer Survivorship
NCT06869512
A Culturally Tailored Smartphone Application for African American Smokers
NCT05188287
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
NCT06494150
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
NCT06130995
Comparison Between Spectacles and Contact Lenses
NCT06905912
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer
NCT06671730
Beta-Adrenergic Modulation of Drug Cue Reactivity
NCT05587361
tDCS for Post-Stroke Cognitive Impairment
NCT06516588
The Effects of Diet and Exercise Interventions in Peripheral Artery Disease
NCT03845036
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
NCT05712395
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
NCT06986993
Effects of Social Media Use on Young Adults' E-Cigarette Use
NCT06142877
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT05921253
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
NCT06137040
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
NCT05934669
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
NCT05806814
Digital Chest Tube Drainage System (Thopaz+) Versus Analog in Pediatric Patients
NCT05511987
Neuromodulation and Fatigue
NCT05487131
The Effect of NAD Supplementation on Brain Vascular Health in Aging
NCT05483465
Cannabis Use on Sedation for Oral Surgery Procedures
NCT05873465
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 40 |
| Phase 3 | 8 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the University of Oklahoma pipeline
80 recruiting of 358 indexed (22% open); 196 completed (55%).
Phase mix: 26 late (III/IV) vs 88 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Oklahoma: open-pipeline peers nationwide
Peers matched on 358 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 358 trials (± recruiting share)
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of Arizona · 349 trials · 16% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this University of Oklahoma page
358 registered trials is a research-attention snapshot, not an endorsement of University of Oklahoma or any single study.
- 80 of University of Oklahoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Oklahoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Oklahoma pipeline card: 358 registered trials from official public datasets.Report a data error.